~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to…
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company…
- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments -- Dermata plans to launch…
Partnership integrates customized kitting, just-in-time operations, and nationwide distribution to accelerate decentralized and hybrid trials NEW BRUNSWICK, NEW JERSEY /…
Powered by the data and AI capabilities of SAS Viya, the life sciences solution streamlines drug development to deliver new…
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…
Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding…
IM8’s Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor’s Bullish Outlook Cantor Notes PRE’s ~$120M Liquidity and 387 BTC…
Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024…
– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data –…